application): The targets of antifolate drugs are the parasite dihydropteroate synthase (DHPS) and, in protozoa, the bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS). Their activities are essential for folate biosynthesis and homeostasis and thymidylate biosynthesis. Inhibition of any of these enzymes will result in the cessation of thymidylate and DNA synthesis and death. A large number of substrate analogues have been tested for inhibition of these enzymes; many of them have been found efficacious in the treatment of infectious and neoplastic diseases. Although it is well known that the potency of these drugs varies among microbial DHFRs, there has been no attempt to assess their efficacy in inhibiting the target C. parvum enzyme. The applicants have previously expressed C. parvum DHFR-TS and human DHFR genes in E. coli, purified the active recombinant enzymes, and developed a microtiter plate-based assay to measure inhibitor I50s and Kis. The applicants have also homology-modeled the tertiary structure of the DHFR domain and applied a docking program to the model to identify candidate inhibitors. The investigators propose to: (1) determine the kinetic constants of distinct C. parvum DHFR-TS enzymes from bovine and human isolates; (2) identify lead inhibitors by screening rationally and empirically selecting candidates by using recombinant enzymes, and refining leads by molecular modeling and structure-activity relationship studies; (3) purify sufficient mass of the recombinant enzyme for crystallization and structure determination; (4) employ a short-term epithelial cell culture system to examine folate synthesis and thymidine salvage by intracellular parasites; and (5) investigate the permeability properties of the C. parvum dense band-feeder organelle by microinjection of fluorescent tracers into the host cell cytoplasm and microscopic observation of their intracellular trafficking.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI040319-04
Application #
2887298
Study Section
Special Emphasis Panel (ZAI1-VSG-A (60))
Program Officer
Laughon, Barbara E
Project Start
1996-09-01
Project End
2000-11-30
Budget Start
1999-06-01
Budget End
2000-11-30
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Leav, Brett A; Mackay, Malanie R; Anyanwu, Akudo et al. (2002) Analysis of sequence diversity at the highly polymorphic Cpgp40/15 locus among Cryptosporidium isolates from human immunodeficiency virus-infected children in South Africa. Infect Immun 70:3881-90
Bonnin, A; Ojcius, D M; Souque, P et al. (2001) Characterization of a monoclonal antibody reacting with antigen-4 domain of gp900 in Cryptosporidium parvum invasive stages. Parasitol Res 87:589-92
Nelson, R G; Rosowsky, A (2001) Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations. Antimicrob Agents Chemother 45:3293-303
Brophy, V H; Vasquez, J; Nelson, R G et al. (2000) Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae. Antimicrob Agents Chemother 44:1019-28
Strong, W B; Nelson, R G (2000) Gene discovery in Cryptosporidium parvum: expressed sequence tags and genome survey sequences. Contrib Microbiol 6:92-115
Strong, W B; Nelson, R G (2000) Preliminary profile of the Cryptosporidium parvum genome: an expressed sequence tag and genome survey sequence analysis. Mol Biochem Parasitol 107:Jan-32
Strong, W B; Gut, J; Nelson, R G (2000) Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products. Infect Immun 68:4117-34
Gut, J; Nelson, R G (1999) Cryptosporidium parvum: lectins mediate irreversible inhibition of sporozoite infectivity in vitro. J Eukaryot Microbiol 46:48S-49S
Gut, J; Nelson, R G (1999) Cryptosporidium parvum: synchronized excystation in vitro and evaluation of sporozoite infectivity with a new lectin-based assay. J Eukaryot Microbiol 46:56S-57S